NO302028B1 - Substituerte heterocykliske karboksylsyreamidestere og deres anvendelse for fremstilling av legemidler - Google Patents
Substituerte heterocykliske karboksylsyreamidestere og deres anvendelse for fremstilling av legemidlerInfo
- Publication number
- NO302028B1 NO302028B1 NO944161A NO944161A NO302028B1 NO 302028 B1 NO302028 B1 NO 302028B1 NO 944161 A NO944161 A NO 944161A NO 944161 A NO944161 A NO 944161A NO 302028 B1 NO302028 B1 NO 302028B1
- Authority
- NO
- Norway
- Prior art keywords
- drugs
- manufacture
- carboxylic acid
- acid esters
- substituted heterocyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Quinoline Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4337270A DE4337270A1 (de) | 1993-11-02 | 1993-11-02 | Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel |
| DE19944434288 DE4434288A1 (de) | 1994-09-26 | 1994-09-26 | Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO944161D0 NO944161D0 (no) | 1994-11-01 |
| NO944161L NO944161L (no) | 1995-05-03 |
| NO302028B1 true NO302028B1 (no) | 1998-01-12 |
Family
ID=25930886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO944161A NO302028B1 (no) | 1993-11-02 | 1994-11-01 | Substituerte heterocykliske karboksylsyreamidestere og deres anvendelse for fremstilling av legemidler |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US5658933A (no) |
| EP (1) | EP0650960B1 (no) |
| JP (1) | JPH07224039A (no) |
| KR (1) | KR950014069A (no) |
| CN (1) | CN1084736C (no) |
| AT (1) | ATE149485T1 (no) |
| AU (1) | AU689135B2 (no) |
| CA (1) | CA2134865A1 (no) |
| CZ (1) | CZ287767B6 (no) |
| DE (1) | DE59401923D1 (no) |
| DK (1) | DK0650960T3 (no) |
| ES (1) | ES2101420T3 (no) |
| GR (1) | GR3023177T3 (no) |
| HK (1) | HK1006712A1 (no) |
| IL (1) | IL111455A0 (no) |
| NO (1) | NO302028B1 (no) |
| NZ (1) | NZ264822A (no) |
| PH (1) | PH31264A (no) |
| PL (1) | PL179687B1 (no) |
| RU (1) | RU2145959C1 (no) |
| TW (1) | TW330202B (no) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6046219A (en) * | 1995-01-20 | 2000-04-04 | Cornell Research Foundation, Inc. | Method for the treatment of conditions mediated by collagen formation together with cell proliferation by application of inhibitors of protein hydroxylation |
| IL135495A (en) * | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid |
| AU5762896A (en) * | 1996-04-30 | 1997-11-19 | Hoechst Aktiengesellschaft | 3-alkoxypyridine-2-carboxylic acid amide esters, their preparation and the ir use as drugs |
| JPH1067674A (ja) * | 1996-06-19 | 1998-03-10 | Advanced Sukin Res Kenkyusho:Kk | 細胞外マトリツクスの異常蓄積抑制剤 |
| DE19746287A1 (de) * | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| AU771975B2 (en) | 1998-11-04 | 2004-04-08 | Meiji Seika Kaisha Ltd. | Picolinamide derivatives and pest controllers containing the same as the active ingredient |
| FR2803592A1 (fr) * | 2000-01-06 | 2001-07-13 | Aventis Cropscience Sa | Nouveaux derives de l'acide 3-hydroxypicolinique, leur procede de preparation et compositions fongicides les contenant. |
| US6528649B2 (en) | 2000-05-30 | 2003-03-04 | Neurogen Corporation | Imidazoloisoquinolines |
| CN101664552B (zh) * | 2001-12-06 | 2013-04-10 | 法布罗根股份有限公司 | 低氧诱导因子(HIF)α的稳定化 |
| US20030176317A1 (en) | 2001-12-06 | 2003-09-18 | Volkmar Guenzler-Pukall | Stabilization of hypoxia inducible factor (HIF) alpha |
| EP2295060B1 (en) | 2001-12-06 | 2018-10-31 | Fibrogen, Inc. | Treatment or prevention of ischemic or hypoxic conditions |
| US7618940B2 (en) | 2002-12-06 | 2009-11-17 | Fibrogen, Inc. | Fat regulation |
| US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
| US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
| PL1644336T3 (pl) | 2003-06-06 | 2011-07-29 | Fibrogen Inc | Związki heteroarylowe zawierające azot i ich zastosowanie w zwiększaniu poziomu endogennej erytropoetyny |
| JP4792048B2 (ja) | 2005-03-02 | 2011-10-12 | ファイブロゲン インコーポレイティッド | チエノピリジン化合物およびその使用方法 |
| JP5390184B2 (ja) * | 2005-06-06 | 2014-01-15 | ファイブローゲン、インコーポレーテッド | 貧血の改良された治療方法 |
| CN101242817B (zh) | 2005-06-15 | 2016-08-31 | 菲布罗根公司 | HIF1α调节剂在治疗癌症中的用途 |
| MX2008009581A (es) | 2006-01-27 | 2009-01-07 | Fibrogen Inc | Compuestos de cianoisoquinolina que estabilizan el factor inducible hipoxia (fih). |
| JP2009527562A (ja) * | 2006-02-21 | 2009-07-30 | アムゲン インコーポレイティッド | ホスホジエステラーゼ１０阻害剤としてのシンノリン誘導体 |
| AU2007223801A1 (en) * | 2006-03-08 | 2007-09-13 | Amgen Inc. | Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors |
| MX2008012734A (es) | 2006-04-04 | 2009-01-29 | Fibrogen Inc | Compuestos pirrolo- y tiazolo-piridina como moduladores del factor inducible de hipoxia (hif). |
| AU2013231191B2 (en) * | 2006-06-23 | 2015-09-03 | Glaxosmithkline Llc | Prolyl hydroxylase inhibitors |
| PE20080209A1 (es) * | 2006-06-23 | 2008-05-15 | Smithkline Beecham Corp | Derivados de glicina como inhibidores de prolil hidroxilasa |
| EP3026044B8 (en) * | 2006-06-26 | 2018-12-19 | Akebia Therapeutics, Inc. | Prolyl hydroxylase inhibitors and methods of use |
| EP2041072B1 (en) * | 2006-06-28 | 2013-09-11 | Sanofi | Cxcr2 antagonists |
| JP5352455B2 (ja) * | 2006-06-30 | 2013-11-27 | サノフイ | Ｃｘｃｒ２阻害剤 |
| TW200845991A (en) | 2007-01-12 | 2008-12-01 | Smithkline Beecham Corp | N-substituted glycine derivatives: hydroxylase inhibitors |
| US8962530B2 (en) | 2007-06-27 | 2015-02-24 | Regents Of The University Of Colorado | Inflammatory bowel disease therapies |
| US8927591B2 (en) | 2008-11-14 | 2015-01-06 | Fibrogen, Inc. | Thiochromene derivatives as HIF hydroxylase inhibitors |
| US8937078B2 (en) | 2009-02-10 | 2015-01-20 | Janssen Pharmaceutica Nv | Quinazolinones as prolyl hydroxylase inhibitors |
| CN102595896B (zh) * | 2009-11-06 | 2016-02-17 | 爱尔皮奥治疗有限公司 | 提高低氧诱导因子-1α的稳定性的方法 |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| US8921389B2 (en) | 2011-02-02 | 2014-12-30 | Fibrogen, Inc. | Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase |
| NO2686520T3 (no) | 2011-06-06 | 2018-03-17 | ||
| WO2012170439A1 (en) * | 2011-06-06 | 2012-12-13 | The Ohio State University | Methods for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer |
| HUE052128T2 (hu) | 2011-10-25 | 2021-04-28 | Janssen Pharmaceutica Nv | Eljárás az 1-(5,6-diklór-1H-benzo[d]imidazol-2-il)-1H-pirazol-4-karbonsav meglumin sója kristályainak elõállítására |
| US9409892B2 (en) | 2012-03-09 | 2016-08-09 | Fibrogen, Inc. | 4-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors |
| ES2631655T3 (es) | 2012-07-16 | 2017-09-01 | Fibrogen, Inc. | Procedimiento para fabricar compuestos de isoquinolina |
| SI3470397T1 (sl) | 2012-07-16 | 2022-07-29 | Fibrogen, Inc. | Kristalinične oblike zaviralca prolil hidroksilaze |
| US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
| KR102233081B1 (ko) | 2013-01-24 | 2021-03-29 | 피브로겐, 인크. | 〔[1-시아노-5-(4-클로로페녹시)-4-하이드록시-아이소퀴놀린-3-카보닐]-아미노〕-아세트산의 결정 형태 |
| CN114404414A (zh) | 2013-06-13 | 2022-04-29 | 阿克比治疗有限公司 | 用于治疗贫血症的组合物和方法 |
| AR099354A1 (es) | 2013-11-15 | 2016-07-20 | Akebia Therapeutics Inc | Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos |
| KR20170099928A (ko) * | 2014-12-30 | 2017-09-01 | 다우 아그로사이언시즈 엘엘씨 | 살진균 활성을 갖는 피콜린아미드 |
| WO2016118858A1 (en) | 2015-01-23 | 2016-07-28 | Akebia Therapeutics, Inc. | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof |
| CN106146395B (zh) * | 2015-03-27 | 2019-01-01 | 沈阳三生制药有限责任公司 | 3-羟基吡啶化合物、其制备方法及其制药用途 |
| BR112017021097B1 (pt) | 2015-04-01 | 2024-01-02 | Akebia Therapeutics, Inc | Formulação de dosagem oral e seu uso |
| TWI822776B (zh) | 2018-05-09 | 2023-11-21 | 美商阿克比治療有限公司 | 用於製備2-[[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基]乙酸之方法 |
| JP7470106B2 (ja) * | 2019-04-26 | 2024-04-17 | 株式会社カネカ | Ｖａｄａｄｕｓｔａｔ中間体の製造方法 |
| CN110305143B (zh) * | 2019-07-19 | 2021-03-09 | 济南新科医药科技有限公司 | 一种呋喃[2，3-c]并吡啶衍生物及其制备方法和用途 |
| US11524939B2 (en) | 2019-11-13 | 2022-12-13 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4015255A1 (de) * | 1990-05-12 | 1991-11-14 | Hoechst Ag | Oxalyl-aminosaeurederivate, verfahren zu ihrer herstellung und ihrer verwendung als arzneimittel zur inhibierung der prolyl-hydroxylase |
| US5192773A (en) * | 1990-07-02 | 1993-03-09 | Vertex Pharmaceuticals, Inc. | Immunosuppressive compounds |
| EP0541042A1 (de) * | 1991-11-05 | 1993-05-12 | Hoechst Aktiengesellschaft | Pyridin-2,4- und 2,5-dicarbonsäureamide und deren Derivate, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel |
| TW352384B (en) * | 1992-03-24 | 1999-02-11 | Hoechst Ag | Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals |
-
1994
- 1994-10-27 ES ES94117017T patent/ES2101420T3/es not_active Expired - Lifetime
- 1994-10-27 AT AT94117017T patent/ATE149485T1/de not_active IP Right Cessation
- 1994-10-27 DK DK94117017.7T patent/DK0650960T3/da active
- 1994-10-27 EP EP94117017A patent/EP0650960B1/de not_active Expired - Lifetime
- 1994-10-27 DE DE59401923T patent/DE59401923D1/de not_active Expired - Fee Related
- 1994-10-28 PL PL94305647A patent/PL179687B1/pl unknown
- 1994-10-28 PH PH49264A patent/PH31264A/en unknown
- 1994-10-30 IL IL11145594A patent/IL111455A0/xx unknown
- 1994-10-31 US US08/332,824 patent/US5658933A/en not_active Expired - Lifetime
- 1994-10-31 AU AU77566/94A patent/AU689135B2/en not_active Ceased
- 1994-10-31 NZ NZ264822A patent/NZ264822A/en unknown
- 1994-11-01 CA CA002134865A patent/CA2134865A1/en not_active Abandoned
- 1994-11-01 RU RU94040163A patent/RU2145959C1/ru active
- 1994-11-01 NO NO944161A patent/NO302028B1/no not_active IP Right Cessation
- 1994-11-01 CZ CZ19942682A patent/CZ287767B6/cs not_active IP Right Cessation
- 1994-11-02 KR KR1019940028870A patent/KR950014069A/ko not_active Application Discontinuation
- 1994-11-02 CN CN94117622A patent/CN1084736C/zh not_active Expired - Fee Related
- 1994-11-02 JP JP6292031A patent/JPH07224039A/ja not_active Abandoned
- 1994-12-05 TW TW083111258A patent/TW330202B/zh active
-
1997
- 1997-04-18 GR GR970400836T patent/GR3023177T3/el unknown
-
1998
- 1998-06-22 HK HK98105874A patent/HK1006712A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DK0650960T3 (da) | 1997-09-01 |
| RU2145959C1 (ru) | 2000-02-27 |
| ES2101420T3 (es) | 1997-07-01 |
| NZ264822A (en) | 1997-02-24 |
| JPH07224039A (ja) | 1995-08-22 |
| NO944161L (no) | 1995-05-03 |
| CZ287767B6 (en) | 2001-01-17 |
| PH31264A (en) | 1998-06-18 |
| RU94040163A (ru) | 1997-02-20 |
| AU689135B2 (en) | 1998-03-26 |
| KR950014069A (ko) | 1995-06-15 |
| PL179687B1 (pl) | 2000-10-31 |
| EP0650960A1 (de) | 1995-05-03 |
| CA2134865A1 (en) | 1995-05-03 |
| US5658933A (en) | 1997-08-19 |
| HK1006712A1 (en) | 1999-03-12 |
| GR3023177T3 (en) | 1997-07-30 |
| CN1084736C (zh) | 2002-05-15 |
| DE59401923D1 (de) | 1997-04-10 |
| NO944161D0 (no) | 1994-11-01 |
| IL111455A0 (en) | 1994-12-29 |
| CN1107144A (zh) | 1995-08-23 |
| EP0650960B1 (de) | 1997-03-05 |
| TW330202B (en) | 1998-04-21 |
| AU7756694A (en) | 1995-05-18 |
| PL305647A1 (en) | 1995-05-15 |
| CZ268294A3 (en) | 1995-05-17 |
| ATE149485T1 (de) | 1997-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO302028B1 (no) | Substituerte heterocykliske karboksylsyreamidestere og deres anvendelse for fremstilling av legemidler | |
| NO301880B1 (no) | Substituerte heterocykliske karboksylsyreamider og deres anvendelse for fremstilling av legemidler | |
| HUT70836A (en) | 1-h-indole-3-acetamide spla2 inhibitors, process for producing them and pharmaceutical compositions comprising same compounds | |
| GR3023635T3 (en) | Substituted heterocyclic carboxylic acid amides, their preparation and their use as medicaments. | |
| HUT70205A (en) | 1h-indole-3-acetic acid hydrazide spla2 inhibitors, pharmaceutical compositions comprising them and process for producing thereof | |
| WO1999047497A3 (en) | Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment | |
| NO951147L (no) | Substituerte heterocykliske karboksylsyreamidestere, deres fremstilling og deres anvendelse som legemiddel | |
| AU686104B2 (en) | Substituted amidinonaphthyl ester derivatives | |
| HUT58089A (en) | Process for producing 3-(l-pyroglutamyl)-l-thiazolidine-4-carboxylic aci derivatives and pharmaceutical compositions comprising such compounds as active ingredient | |
| MY112414A (en) | Substituted heterocyclic carboxamide esters, their preparation and their use as pharmaceuticals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |
Free format text: LAPSED IN MAY 2003 |